Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

MAT2A inhibitor S-095035

An orally bioavailable inhibitor of methionine adenosyltransferase II alpha (MAT2A), with potential antineoplastic activity. Upon oral administration, MAT2A inhibitor S-095035 targets, binds to and inhibits the activity of MAT2A, a metabolic enzyme responsible for the production of S-adenosyl-L-methionine (SAM), a primary donor of methyl groups in cellular transmethylation reactions that regulate gene expression, cell growth, and differentiation. Inhibition of MAT2A may inhibit proliferation in methylthioadenosine phosphorylase (MTAP)-deleted cancers that rely heavily on SAM synthesis. MAT2A activity is essential in cancer cells deficient in MTAP, a critical enzyme in the methionine salvage pathway, that is deleted in a variety of human cancers.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:methionine adenosyltransferase 2 alpha inhibitor S-095035
Code name:S 095035
S-095035
S095035
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search